Search clinical trials for: HM15136

Total 3 results

Hanmi Pharmaceutical Company Limited

Completed

A First-in-Human, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136 in Healthy Subjects

Pharmacology

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Recruiting

HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

Congenital Hyperinsulinism

United States, Germany, United Kingdom, Israel
Hanmi Pharmaceutical Company Limited

Completed

Study for Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities

Type2 Diabetes | Obese With Comorbidities | Overweight With Comorbidities

United States

3

Subscribe